Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced its participation in the 8th Annual Biotech ShowcaseTM Conference in San Francisco, CA on January 11-13, 2016.

Mr. Quang Pham, Founder and CEO, will discuss recent Company developments in his presentation on Tuesday, January 12 at 2:45pm PST at the Parc 55 Hotel where the conference is being held.

Espero Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for GoNitro™ for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. The FDA has set an action date of June 10, 2016 to complete its review, as per the Prescription Drug User Fee Act (PDUFA).

GoNitroTM is a novel nitroglycerin sublingual powder formulation developed by Pohl-Boskamp, a fully-integrated German pharmaceutical company with a 175 year operating history. Espero has an exclusive Licensing and Distribution Agreement with Pohl-Boskamp in the U.S. that includes GoNitroTM as well as Nitrolingual® Pumpspray, which was approved by FDA in 1997.

About Biotech Showcase™

Biotech Showcase™ 2016 is one of the industry's largest annual healthcare investor and partnering conferences, with more than 225 company presentations and 2,100 attendees expected. Attendees include biopharmaceutical and life science company executives, investors in private and public companies, sector analysts, bankers and industry professionals. The conference is run concurrently with, but independently from, the JP Morgan Healthcare Conference in San Francisco, one of the largest and most influential international healthcare conferences.

About Espero

Espero Pharmaceuticals, Inc., headquartered in Jacksonville, Florida, is an emerging growth specialty pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients. Espero is focused on compounds with proven safety and efficacy administered via novel delivery solutions in the cardiovascular and other specialty therapeutic categories.